➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Merck
Express Scripts
Moodys

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Verapamil hydrochloride - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for verapamil hydrochloride and what is the scope of patent protection?

Verapamil hydrochloride is the generic ingredient in seven branded drugs marketed by Mylan, Recro Gainesville, Gd Searle Llc, Mt Adams, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Amneal, Areva Pharms, Caplin, Exela Pharma Scs Llc, Micro Labs, Somerset, Somerset Theraps Llc, Pfizer, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, Watson Labs, and Yaopharma Co Ltd, and is included in sixty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for verapamil hydrochloride. Thirty-nine suppliers are listed for this compound.

Recent Clinical Trials for verapamil hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Hospitalier Universitaire de NicePhase 4
Tanta UniversityEarly Phase 1
Assiut UniversityEarly Phase 1

See all verapamil hydrochloride clinical trials

Medical Subject Heading (MeSH) Categories for verapamil hydrochloride
Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
VERELAN PM CAPSULE, EXTENDED RELEASE;ORAL verapamil hydrochloride 020943 2006-07-20
VERELAN PM CAPSULE, EXTENDED RELEASE;ORAL verapamil hydrochloride 020943 2006-05-19
COVERA-HS TABLET, EXTENDED RELEASE;ORAL verapamil hydrochloride 020552

US Patents and Regulatory Information for verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ivax Sub Teva Pharms VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 074330-001 Jan 31, 1994 AB RX No No   Start Trial   Start Trial   Start Trial
Mutual Pharm VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET;ORAL 070483-001 Sep 24, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 DISCN No No   Start Trial   Start Trial   Start Trial
Apotex Corp VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 200878-001 Apr 20, 2012 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996   Start Trial   Start Trial
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996   Start Trial   Start Trial
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998   Start Trial   Start Trial
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Merck
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.